Receptos rises on deal chatter, with AstraZeneca, Teva and Gilead in the mix

A rash of unnamed-source reports claim Receptos ($RCPT) has shaken off multibillion-dollar advances from some of the world's biggest drugmakers, sending the San Diego biotech's shares ever higher as it advances its autoimmune treatment. According to the U.K.'s Independent, people close to the situation say AstraZeneca ($AZN) pitched a $200-a-share deal to Receptos, valuing the biotech at more than $6 billion, only to be rebuffed. Gilead Sciences ($GILD) and Teva ($TEVA) have also made overtures for the company, according to the Independent, but haven't gotten anywhere. Similar stories proliferated around the Internet on Wednesday, from sites reputable and otherwise, and Receptos' value has risen more than 10% since the rumors first emerged. Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.